Cargando…

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan

Objective. The aim of this study was to determine whether biologic-free remission of RA is possible with discontinuation of abatacept. Methods. Japanese RA patients in 28-joint DAS with CRP (DAS28-CRP) remission (<2.3) after >2 years of abatacept treatment in a phase II study and its long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Matsubara, Tsukasa, Ohta, Shuji, Mukai, Masaya, Amano, Koichi, Tohma, Shigeto, Tanaka, Yoshiya, Yamanaka, Hisashi, Miyasaka, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372674/
https://www.ncbi.nlm.nih.gov/pubmed/25257039
http://dx.doi.org/10.1093/rheumatology/keu338
_version_ 1782363222315106304
author Takeuchi, Tsutomu
Matsubara, Tsukasa
Ohta, Shuji
Mukai, Masaya
Amano, Koichi
Tohma, Shigeto
Tanaka, Yoshiya
Yamanaka, Hisashi
Miyasaka, Nobuyuki
author_facet Takeuchi, Tsutomu
Matsubara, Tsukasa
Ohta, Shuji
Mukai, Masaya
Amano, Koichi
Tohma, Shigeto
Tanaka, Yoshiya
Yamanaka, Hisashi
Miyasaka, Nobuyuki
author_sort Takeuchi, Tsutomu
collection PubMed
description Objective. The aim of this study was to determine whether biologic-free remission of RA is possible with discontinuation of abatacept. Methods. Japanese RA patients in 28-joint DAS with CRP (DAS28-CRP) remission (<2.3) after >2 years of abatacept treatment in a phase II study and its long-term extension entered this 52 week, multicentre, non-blinded, prospective, observational study. At enrolment, the patients were offered the option to continue abatacept or not. The primary endpoint was the proportion of patients who remained biologic-free at 52 weeks after discontinuation. Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept. Results. Of 51 patients enrolled, 34 discontinued and 17 continued abatacept treatment. After 52 weeks, 22 of the 34 patients (64.7%) remained biologic-free. Compared with the continuation group, the discontinuation group had a similar remission rate (41.2% vs 64.7%, P = 0.144) although they had a significantly higher mean DAS28-CRP score at week 52 (2.9 vs 2.0, P = 0.012). The two groups were also similar with regard to mean HAQ Disability Index (HAQ-DI) score (0.6 for both, P = 0.920), mean change in total Sharp score (ΔTSS; 0.80 vs 0.32, P = 0.374) and proportion of patients in radiographic remission (ΔTSS ≤ 0.5) at the endpoint (64.3% vs 70.6%, P = 0.752). Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment. Non-serious adverse events occurred in three patients who continued or resumed abatacept. Conclusion. Biologic-free remission of RA is possible in some patients after attaining clinical remission with abatacept. Lower baseline HAQ-DI or CRP may predict maintenance of remission or low disease activity after discontinuation of abatacept. Trial registration: UMIN Clinical Trials Registry, http://www.umin.ac.jp/ctr/ (UMIN000004137).
format Online
Article
Text
id pubmed-4372674
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43726742015-03-26 Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan Takeuchi, Tsutomu Matsubara, Tsukasa Ohta, Shuji Mukai, Masaya Amano, Koichi Tohma, Shigeto Tanaka, Yoshiya Yamanaka, Hisashi Miyasaka, Nobuyuki Rheumatology (Oxford) Clinical Science Objective. The aim of this study was to determine whether biologic-free remission of RA is possible with discontinuation of abatacept. Methods. Japanese RA patients in 28-joint DAS with CRP (DAS28-CRP) remission (<2.3) after >2 years of abatacept treatment in a phase II study and its long-term extension entered this 52 week, multicentre, non-blinded, prospective, observational study. At enrolment, the patients were offered the option to continue abatacept or not. The primary endpoint was the proportion of patients who remained biologic-free at 52 weeks after discontinuation. Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept. Results. Of 51 patients enrolled, 34 discontinued and 17 continued abatacept treatment. After 52 weeks, 22 of the 34 patients (64.7%) remained biologic-free. Compared with the continuation group, the discontinuation group had a similar remission rate (41.2% vs 64.7%, P = 0.144) although they had a significantly higher mean DAS28-CRP score at week 52 (2.9 vs 2.0, P = 0.012). The two groups were also similar with regard to mean HAQ Disability Index (HAQ-DI) score (0.6 for both, P = 0.920), mean change in total Sharp score (ΔTSS; 0.80 vs 0.32, P = 0.374) and proportion of patients in radiographic remission (ΔTSS ≤ 0.5) at the endpoint (64.3% vs 70.6%, P = 0.752). Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment. Non-serious adverse events occurred in three patients who continued or resumed abatacept. Conclusion. Biologic-free remission of RA is possible in some patients after attaining clinical remission with abatacept. Lower baseline HAQ-DI or CRP may predict maintenance of remission or low disease activity after discontinuation of abatacept. Trial registration: UMIN Clinical Trials Registry, http://www.umin.ac.jp/ctr/ (UMIN000004137). Oxford University Press 2015-04 2014-09-24 /pmc/articles/PMC4372674/ /pubmed/25257039 http://dx.doi.org/10.1093/rheumatology/keu338 Text en © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Takeuchi, Tsutomu
Matsubara, Tsukasa
Ohta, Shuji
Mukai, Masaya
Amano, Koichi
Tohma, Shigeto
Tanaka, Yoshiya
Yamanaka, Hisashi
Miyasaka, Nobuyuki
Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
title Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
title_full Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
title_fullStr Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
title_full_unstemmed Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
title_short Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
title_sort biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in japan
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372674/
https://www.ncbi.nlm.nih.gov/pubmed/25257039
http://dx.doi.org/10.1093/rheumatology/keu338
work_keys_str_mv AT takeuchitsutomu biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT matsubaratsukasa biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT ohtashuji biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT mukaimasaya biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT amanokoichi biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT tohmashigeto biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT tanakayoshiya biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT yamanakahisashi biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan
AT miyasakanobuyuki biologicfreeremissionofestablishedrheumatoidarthritisafterdiscontinuationofabataceptaprospectivemulticentreobservationalstudyinjapan